David Summa

David Summa

Vorsitzender bei
IONpath, Inc.
Commercial Services
Health Technology
Process Industries

Profil

David W.
Summa
is currently the Executive Chairman at IONpath, Inc. since 2023 and an Advisor at Peaxy, Inc. since 2016.
Previously, he served as the President & Chief Executive Officer at Mendel Biotechnology, Inc. from 1999 to 2002.
He also held positions as a Director at Monsanto Co., Director at Sequoia Pharmaceuticals, Inc., Director at Acumen Pharmaceuticals, Inc., Director at Agrivida, Inc., Director at Alliance of Chief Executives LLC from 2020 to 2021, and Chief Business Officer at Mascoma Corp.
He was a Vice President at Halio, Inc. in 2012.
Prior to that, he worked as a Partner at McKinsey & Co., Inc. from 1989 to 1996.
Additionally, he served as the Executive Vice President at Kiverdi, Inc. in 2015 and as an Operating Partner at Genoa Ventures LLC from 2021 to 2023.
Mr. Summa obtained his undergraduate and graduate degrees from the Massachusetts Institute of Technology in 1981 and 1985, respectively.

Aktive Positionen von David Summa

UnternehmenPositionBeginn
Berater 01.02.2016
Vorsitzender 06.12.2023

Ehemalige bekannte Positionen von David Summa

UnternehmenPositionEnde
Private Equity Investor 01.11.2023
Direktor/Vorstandsmitglied 02.12.2021
Private Equity Investor 02.11.2015
Private Equity Investor 02.10.2012
ACUMEN PHARMACEUTICALS, INC. Direktor/Vorstandsmitglied 02.01.2008
Sehen Sie sich die Erfahrung von David Summa im Detail an

Ausbildung von David Summa

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Beziehungen

94

Beziehungen ersten Grades

14

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Unternehmensverbindungen

Private Unternehmen14

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Process Industries

Commercial Services

Commercial Services

Finance

Commercial Services

Health Services

Process Industries

Finance

Technology Services

  1. Börse
  2. Insiders
  3. David Summa